Patients with hepatocellular carcinoma receive a higher Model for End-Stage Liver Disease (MELD) score.
These patients may undergo liver transplantation earlier than patients with cirrhosis, potentially decreases waiting list mortality.
However, post-liver transplantation survival may be reduced by recurrence of hepatocellular carcinoma.
Dr Stephen Wong and colleagues from Michigan assessed clinical outcomes in 183 patients with Hepatitis B-cirrhosis and no hepatocellular carcinoma.
The research team compared the results to 96 patients with Hepatitis B-hepatocellular carcinoma.
The team assessed patients in the USA Hepatitis B virus-orthotopic liver transplantation study for a median of 30 months from listing.
|78% with hepatocellular carcinoma had liver transplants|
The team found that patients with hepatocellular carcinoma were older, and were more likely to be Asian than patients with Hepatitis B-cirrhosis.
The researchers observed that patients with hepatocellular carcinoma had less severe liver impairment than patients with Hepatitis B-cirrhosis.
Liver transplantation occurred in 78% of patients with hepatocellular carcinoma vs 51% in patients with Hepatitis B-cirrhosis.
Intention-to-treat survival and survival without liver transplantation at 5 years were similar for patients with and without hepatocellular carcinoma.
The researchers identified that higher albumin, and lower MELD were both associated with better intention-to-treat survival.
The team found that hepatocellular carcinoma at listing, and being transplanted was associated with better intention-to-treat survival.
The researchers reported that 94 patients with hepatocellular carcinoma and 75 with Hepatitis B-cirrhosis underwent liver transplantation.
Post-liver transplantation survival and Hepatitis B recurrence at 3 years were similar.
The research team noted that disease recurrence was higher in patients with Hepatitis B-hepatocellular carcinoma than with Hepatitis B-cirrhosis.
The team observed that disease recurrence was the only independent predictor of post-liver transplantation survival.
Dr Wong's team comments, “Despite more advanced liver disease and a lower rate of transplantation, intention-to-treat survival of patients listed for Hepatitis B-cirrhosis was comparable to those with Hepatitis B-hepatocellular carcinoma.”
“This was possibly related to the beneficial effects of antiviral therapy.”